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Exposure of endothelial cells to recombinant human erythro- throid progenitor cells is the primary target for EPO
poietin induces nitric oxide synthase activity. binding [5, 6].
Background. Anemic patients with chronic renal failure re- In hematopoietic cells, EPOR mRNA is expressed atceiving recombinant human erythropoietin (rHuEPO) therapy
moderate levels [7]. EPOR or EPOR mRNA are alsofrequently develop hypertension through an unknown mecha-
expressed on nonhematopoietic cells, including humannism. We hypothesize that EPO receptors (EPORs) on endo-
thelial cells (ECs) in various sites of vasculature may mediate umbilical vein endothelial cell (HUVEC) [8, 9], rat brain
the activities of nitric oxide synthase (NOS) and/or the release capillary endothelial cells (ECs) [10], murine hippocam-
of endothelin-1 (ET-1), contributing to blood pressure changes. pal and cerobrocortical areas [11], and primary cultured
We tested this hypothesis using primary cultures of ECs ob-
hippocampal and cortical neurons [12, 13]. The EPORstained from human coronary artery (HCAEC), pulmonary ar-
are functional in HUVEC and mouse brain.tery (HPAEC), dermis (HDEC), and umbilical vein (HUVEC).
The angiogenic effect of EPO has been studied inMethods. EPORs were measured by 125I-EPO binding. The
effect of EPO on EPOR, ET-1, and NOS mRNA levels was ovariectomized mice in which an injection of EPO into
assessed by quantitative reverse transcription-polymerase chain the uterine cavity promoted blood vessel formation in
reaction. Cellular NOS activity and ET-1 release into the me- the endometrium [14]. EPO stimulates proliferation anddium was measured by the NOSdetect assay and by radioimmu-
migration of human and bovine EC and also angiogen-noassay kits.
esis of the rat thoracic aorta [8, 15].Results. Short-term (4 h) treatment with EPO (4 U/mL) did
not change the number or affinity of EPOR per cell. Neither Many anemic patients with chronic renal failure re-
were there any changes in the amount of EPOR, ET-1, and ceive treatment with recombinant human erythropoietin
NOS transcripts (cDNA/mg of mRNA) nor in ET-1 release (rHuEPO) with beneficial results. The major side-effect
and NOS activity. In HUVEC only, 24-hour exposure to EPO
of this treatment is the development of clinically signifi-caused a threefold increase in NOS transcript. In other cells,
cant hypertension [16–18]. Several factors have been im-EPO treatment for six days increased NOS activity by twofold
to fourfold. plicated in rHuEPO-associated hypertension: an in-
Conclusions. We show that upon extended exposure, EPO crease in hematocrit and red blood cell mass resulting
induces NOS activity but does not affect ET-1 release. These in increased blood viscosity [19], a loss of hypoxic vasodi-
findings indicate that the hypertensive effect of EPO is not
lation [20], a direct vasoconstrictor effect [21], and anlikely to be caused by a direct effect on ECs.
increase in calcium uptake by vascular smooth muscle
cells [22, 23]. Nevertheless, the principal cause of EPO-
induced hypertension is unknown. The angiogenic na-Erythropoietin (EPO) is a glycoprotein hormone that
ture of EPO and the occurrence of EPOR on ECs suggestis the primary regulator of erythropoiesis [1]. EPO is
that EPO may directly stimulate ECs.produced by the kidney in adults and by the liver in fetal
In humans, clinical events such as hypertension andlife [1, 2]. EPO functions through its interaction with a
thrombosis are often localized in specific vessels. Thissingle chain cell surface receptor of the cytokine receptor
pattern, in part, may be due to the heterogeneity of ECsuperfamily [3, 4]. The EPO receptor (EPOR) on ery-
themselves [reviewed in 24, 25]. Since the discovery of
EC-dependent vasodilation by Furchgott and Zawadzki,
ECs have been recognized as an important functionalKey words: erythropoietin, receptor, endothelin, nitric oxide, anemia,
chronic renal failure. unit. Upon induction by vasoactive agents, such as acetyl-
choline and bradykinin, ECs secrete short-lived relaxingReceived for publication August 5, 1999
factor(s) causing relaxation of underlying smooth muscleand in revised form October 20, 1999
Accepted for publication December 2, 1999 cells [reviewed in 26, 27]. One endothelium-derived relax-
ing factor is nitric oxide (NO) [28]. EC-dependent vaso-Ó 2000 by the International Society of Nephrology
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constriction has also been observed in response to various sured in a gamma counter. Nonspecific binding was as-
sessed in the presence of a 100-fold molar excess ofphysiological stimuli such as thrombin [29], hypoxia [30],
and mechanical stretch [31]. Endothelin-1 (ET-1) is the unlabeled EPO added at the start of incubation and
subtracted from the total to calculate net specific binding.most potent vasoconstrictor peptide produced by ECs
[32, 33]. Vascular smooth muscle cells and glomerular
Preparation of RNAmesangial cells respond to ET-1 by cellular contraction
and proliferation [34, 35]. To date, very little information Approximately 1 to 5 3 107 cells, either treated with
rHuEPO (4 U/mL) for four hours or untreated, wereis available on the effect of EPO on endothelium from
different vascular sites. washed twice with PBS, and RNA was extracted with
TRIzol reagent as recommended by the supplier (LifeIn this study, we obtained primary cultures of EC
prepared from various sites of human vasculature and Technologies, Grand Island, NY, USA). mRNA was ad-
sorbed onto oligo(dT)-cellulose columns (Qiagen, Va-examined the levels of EPO binding to the cells and the
effect of EPO on EPOR, ET-1, and NO synthase (NOS) lencia, CA, USA). The total amount and concentration
of mRNA were determined spectrophotometrically.mRNA expression by quantitative reverse transcription-
polymerase chain reaction (RT-PCR). We also measured
Reverse transcription of RNA and synthesis of cDNAthe effect of EPO on ET-1 release into the culture me-
dium and endothelial NOS enzyme activities. We found An aliquot of mRNA (0.5 to 1 mg) was incubated at
428C for one hour in 20 mL of 10 mmol/L Tris-HCl, pHthat EPORs are present on all ECs tested and that
EPOR, ET-1, and NOS mRNA levels are unaffected by 8.8, containing 50 mmol/L KCl, 0.1% Triton X-100, 5
mmol/L MgCl2, 1 mmol/L each dNTPs, 20 units oftreatment with EPO. However, the extended exposure
of vascular ECs to EPO at super-physiological concen- RNAsin, and 0.5 mg oligo dT15 primer. The cDNA was
synthesized by primer extension using 15 units of aviantrations induced NOS activity, which may contribute to
the regulation of blood pressure. myeloblastosis virus (AMV) reverse transcriptase per mg
of RNA (Promega, Madison, WI, USA).
METHODS Preparation of internal standard DNA and
amplification of cDNACells and cell culture
Primary cultures of human ECs, prepared from umbili- An internal standard was constructed by PCR ampli-
fication of genomic DNA using the following primer sets:cal vein (HUVEC), coronary artery (HCAEC), pulmonary
artery (HPAEC), and dermis (HDEC) were purchased (1) 59-GCACCGAGTGTGTGCTGAGC-39 and 59-GGT
CAGCAGCACCAGGATGA-39 for hEPOR [36], (2)from Clonetics (San Diego, CA, USA). Cells were cul-
tured at 378C in modified MCDB 131 medium (Clonetics) 59-CCGTATGGACTTGGAAGCCC-39 and 59-CTGG
TTTGTCTTAGGTGTTCC-39 for ET-1 [37], and (3)supplemented with 5% fetal bovine serum (FBS; Hyclone
Laboratories, Logan, UT, USA) in an air-5% CO2 atmo- 59-CCTCCCCCCGGCTGGGTGCG-39 and 59-GCAC
CTCCAGAAGCGTGGG-39 for NOS [38]. The samesphere at constant humidity. Cells were maintained in
continuous culture and used within three to five passages. primer sets were used for cDNA amplification.
Quantitative polymerase chain reaction125I-EPO binding reactions
For binding studies (3-[125I]iodotyrosyl)rHuEPO (Am- To quantitate gene-specific mRNA, multiple reaction
mixtures were prepared with known amounts of cDNA.ersham Corp., Arlington Heights, IL, USA) was used.
The experimental procedures for the binding of 125I-EPO Serial dilutions of internal standard cDNA and [a-32P]
CTPwere added to each tube and coamplified. The prod-to ECs have been reported elsewhere [8]. Briefly, con-
fluent monolayers of ECs (1 3 106 cells/well) were ucts were analyzed by gel electrophoresis. The bands
representing gene-specific cDNA and the standard DNAwashed with binding medium (0.05 mol/L phosphate
buffer, pH 7.4, containing 150 mmol/L NaCl, 68 mmol/L fragment were recovered and counted, and the results
were plotted as cpm versus the concentration of externalCaCl2, 50 mmol/L MgCl2, and 1 mg/mL human serum
albumin) and incubated at 228C with 1.0 mL binding standard.
buffer containing 60,000 counts per min (cpm) of 125I-EPO
Endothelin-1 assay(Sp. Act. 300 to 900 Ci/mmol). At the end of specified
time of incubation, wells were gently washed three times The medium from cultured ECs, either exposed for
four hours to rHuEPO (4 U/mL) or untreated, was har-with prewarmed phosphate-buffered saline (PBS) con-
taining 1% FBS, and the cells were then solubilized in vested and centrifuged at 500 3 g at 48C for 10 minutes.
The recovered supernatants were then stored at 2708C.lysis buffer [20 mmol/L HEPES, pH 7.4, 1% Triton
X-100, 10% (vol/vol) glycerol, and 0.1 mg/mL of bovine ET-1 determinations were performed using an ET-1 radio-
immunoassay kit (Peninsula Lab., Belmont, CA, USA).serum albumin]. The radioactivity of the lysates was mea-
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Fig. 1. Kinetics of 125I-recombinant human
erythropoietin (rHuEPO) binding to endo-
thelial cells. Monolayers of human endo-
theial cells prepared from (A) umbilical vein
(HUVEC), (B) coronary artery (HCAEC),
(C) dermis (HDEC), and (D) pulmonary ar-
tery (HPAEC) were incubated with 60,000
cpm of 125I-EPO (Sp. act. 166 Ci/mmol) in 1.0
mL phosphate buffered saline (PBS) con-
taining CaCl2 and MgCl2 for increasing time
intervals at 228C. At the end of each time
point, cells were washed, and the specific ra-
dioactivity associated with each well was de-
termined as described in the Methods section.
The results from three independent experi-
ments are shown. Error bars represent stan-
dard errors (N 5 3).
Nitric oxide synthase assay nalization and degradation of EPO as the binding assays
were performed at 228C. The concentration dependenceConfluent monolayers of ECs, either treated with
of EPO binding was measured over the range from 1 torHuEPO (4 U/mL) daily for six days or untreated, were
18 nmol/L (Fig. 2). Specific binding was found to bewashed twice with PBS, harvested, and homogenized.
saturable. The mean number of EPOR per cell was calcu-The homogenate was centrifuged, and the supernatant
lated by Scatchard plot analysis (Fig. 3). The calculatedprotein concentration was adjusted to 1 mg/mL. The
number of binding sites was 44,668 for HUVEC, 49,845NOS activity was measured using a NOSdetect assay kit
for HCAEC, 56,106 for HDEC, and 58,093 for HPAEC,according to the supplier’s specification (Stratagene, La
while the dissociation constants (Kd) were 5.6 3 1029Jolla, CA, USA).
mol/L for HUVEC, 7.7 3 1029 mol/L for HCAEC, 1.10 3
1028 mol/L for HDEC, and 1.50 3 1028 mol/L for
RESULTS HPAEC. Exposure of cells for two days to EPO resulted
125I-EPO binding study in no significant change in the number of receptor sites
(data not shown).To compare binding of 125I-EPO to EC from various
vascular sites, cells were exposed to 125I-EPO with or
Quantitation of mRNA expressionwithout a 100-fold excess of unlabeled EPO for increas-
To confirm that EPO binding correlated with EPORing time intervals. The time dependence of binding of
gene expression, ECs were cultured with or without EPO125I-rHuEPO to ECs from various sources is shown in
for four hours, and EPOR mRNA was measured byFigure 1. All ECs readily bound 125I-EPO, and the specific
quantitative RT-PCR. The results are shown in Figurebinding increased with time, reaching a plateau in about
4. The expected 197 bp cDNA fragment and 285 bpfour hours for HUVEC and HCAEC. The plateauing
internal standard DNA were amplified from ECs fromtime was slightly longer (approximately 6 h) for HDEC
all sources. Further cloning and sequencing confirmedand HPAEC. The fluctuation of increase binding in vari-
ous ECs may correspond to the differences in the inter- that the 197 bp fragment represented hEPOR mRNA.
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Fig. 2. Dose response of 125I-EPO binding to
endothelial cells. Confluent monolayers of (A)
HUVEC, (B) HCAEC, (C) HDEC, and (D)
HPAEC were washed and incubated with in-
creasing amounts of 125I-EPO (1 to 18 pmol) for
four hours at 228C. Monolayers were washed,
and the specific radioactivity associated with
each well was determined as described in the
Methods section. The results from three inde-
pendent experiments are shown. Error bars
represent standard errors (N 5 3).
The amount of hEPOR-specific cDNA/mg of mRNA ng for HPAEC, 2.6 3 1022 ng for HCAEC, and 0.34 3
1022 ng for HDEC. These values were unchanged indetermined in duplicate by quantitative PCR was 5.1 3
1024 ng for HUVEC, 11.0 3 1024 ng for HPAEC, 4.0 3 HCAEC, HPAEC, and HDEC cultures exposed to
rHuEPO. However, the level of ET-1 transcript rose1024 ng for HCAEC, and 64.0 3 1024 for HDEC. With
the exception of HCAEC, treatment of these cells with twofold in EPO-treated HUVEC cultures. Treatment of
HUVEC cells with EPO for 1, 2, 4, 6, and 24 hours hadEPO for up to four hours had little or no effect on EPOR
mRNA. In contrast, a twofold increase of EPOR mRNA no significant effect on ET-1 mRNA (data not shown).
Table 3 shows ET-1 release by cultured HUVEC,was measured in EPO-treated HCAEC culture (Table
1). Treatment of HUVEC cells with EPO for 1, 2, 4, 6, HCAEC, HPAEC, and HDEC during a four-hour treat-
ment with 4 U/mL rHuEPO. All cells released ET-1 intoand 24 hours had little or no effect on EPOR mRNA
(data not shown). the media. About 35 to 48 pg of ET-1 were released by
2 3 105 cells. These values also did not change with EPO
Effects of rHuEPO on ET-1 gene expression and treatment, consistent with the results shown in Table 2.
ET-1 secretion
Effect of rHuEPO on NOS activityA direct link between ET-1 and EPO has been estab-
lished from the findings that HUVECs have EPOR [8, 9] Nitric oxide is thought to play a central role in vascular
homeostsis. NO, a heterodiatomic free radical product,and that rHuEPO increases ET-1 release by bovine pul-
monary artery ECs [39]. We therefore examined the is generated through the oxidation of l-arginine to l-cit-
rulline by NOS. NO has been demonstrated to inhibiteffect of EPO on ET-1 expression by cultured HUVEC,
HCAEC, HPAEC, and HDEC. As shown in Figure 5, thrombosis, cytokine-induced vascular cell adhesion
molecule-1 (VCAM) expression, leukocyte adhesion toa 290 bp ET-1–specific partial cDNA fragment and a
450 bp internal standard DNA were amplified by ET-1 endothelium, and smooth muscle proliferation and mi-
gration [40–42]. To investigate the effect of EPO onprimer sets and RT-PCR. The 290 bp fragment was
cloned, and its identity confirmed by sequencing. The NOS activity, we measured NOS mRNA levels by RT-
PCR. The results are shown in Figure 6. Partial cDNAquantitative values are shown in Table 2. The amount
of ET-1–specific cDNA/mg of mRNA in duplicate quan- fragments (approximately 230 bp) and standard DNA
(approximately 500 bp) were isolated, cloned, and char-titative PCR was 2.8 3 1022 ng for HUVEC, 3.8 3 1022
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Fig. 3. Scatchard analysis of 125I-EPO binding
to endothelial cells. Plots represent Scatchard
analyses of binding data shown in Figure 2.
The data suggest the presence of a single class
receptor with different affinities in different
cell types. For (A) HUVEC, Kd 5 5.6 3 1029
mol/L and 44,668 receptor sites per cell; (B)
HCAEC, Kd 5 7.7 3 1029 mol/L and 49,845
receptor sites per cell; (C) HDEC, Kd 5 1.10 3
1028 mol/L and 56,106 receptor sites per cell;
(D) HPAEC, Kd 5 1.5 3 1028 mol/L and
58,093 receptor sites per cell.
acterized by sequencing. The quantitative values are at a low ligand concentration in Scatchard analysis indi-
shown in Table 4. The NOS-specific mRNA in ECs var- cates the possibility of more than one binding site. Our
ied from 1.0 3 1023 to 1.8 3 1023 ng/mg of mRNA. finding of a large number of relatively low-affinity bind-
Exposure of the cells to rHuEPO had little effect. How- ing sites on all EC types tested (Fig. 3) is consistent with
ever, the presence of EPO for 24 hours induced a three- the findings of Anagnostou et al [8]. This is in contrast
fold increase in NOS-specific mRNA (5.4 3 1023 ng with earlier studies that measured the binding of EPO
cDNA/mg of mRNA) compared with control cultures to its receptors and showed that erythroid progenitor
of HUVEC (1.8 3 1023 ng cDNA/mg of mRNA). The cells have only a small number of cell surface receptors
increase values were maintained for up to six days upon [43–45]. The low number of receptors per cell for growth
daily removal and replenishment with fresh EPO-supple- factors is common in hematopoietic cells [46].
mented medium. Short-term exposure for one, two, four, The ligand affinity of EPOR expressed on EC is much
and six hours to EPO, HUVEC exhibited no effect on lower than that on erythroid cells; the Kd for EPO bind-
NOS-specific mRNA (data not shown). ing to EPOR on EC varies from approximately 5 to 15
To confirm that the increased NOS-specific mRNA nmol/L [8, 10], while the Kd for the high-affinity receptorresulted in increased NOS activity, we determined the on erythroid cells is approximately 50 pmol/L [47]. The
effect of EPO on NOS activity. As shown in Table 5,
reason for the expression of only the low-affinity recep-
long-term EPO treatment resulted in a twofold to four-
tor on ECs is unclear. Expression of only the low-affinityfold increase in NOS activity in all ECs.
receptor might be crucial to prevent unregulated angio-
genesis by endogenous EPO. The presence of EPOR on
DISCUSSION ECs may originate from the close relationship between
vasculogenesis and hematopoiesis in early developmentThe present study demonstrates that ECs prepared
[48] and between angiogenesis and hematopoiesis laterfrom various regions of the vascular tree bind EPO in
a dose-dependent manner. The scattering of data points in development [49].
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Fig. 4. Polymerase chain reaction (PCR) analysis of human erythropoietin receptor (hEPOR) transcripts in control and EPO-treated HUVEC,
HPAEC, HDEC, and HCAEC. Monolayers of HUVEC, HCAEC, HDEC, and HPAEC were incubated with EPO (4 U/mL) for four hours or
were untreated, and mRNA was prepared as described in the Methods section. cDNA was reverse transcribed from mRNA isolated from respective
endothelial cells. Multiple reactions for hEPOR-specific PCR amplification of cDNA were carried out with hEPOR primers. Prior to amplification,
increasing amounts of standard DNA and [a-32P]dCTP were added to each reaction. (A) The amplification products were resolved by agarose gel
electrophoresis. Left panel show control gels and right panels show EPO-treated gels (upper band 285 bp standard DNA and lower band 197 bp
hEPOR cDNA; bp, size markers). (B) For quantitation, the hEPOR and the standard DNA bands were cut, the radioactivity present in each
band was determined and plotted against the amount of standard added to each reaction mixture. Symbols are: (d) standard DNA; (j) hEPOR-
specific PCR product. The amount of standard corresponding to the point at which the two PCR products are equal is an indication of the amount
of hEPOR cDNA present.
Compared with OCI-M1 or other human erythroid
cell lines, HUVECs have many more EPOR and a lower
Table 1. Quantitation of human erythropoietin receptor expression of EPOR mRNA [9]. In our study, the mean
(hEPOR)-specific mRNA expression
number of EPOR per cell varied from 44,668 to 58,093,
Control EPO-treated but the quantity of EPOR mRNA was less than the
ECs ng cDNA/lg of mRNA amount reported for OCI-M1 cells. The significance of
this discrepancy is not clear. In erythroid cells, less thanHUVEC 5.1 31024 5.531024
HPAEC 11 31024 9.231024 5% of the newly synthesized EPORs are found on the
HCAEC 4.0 31024 9.031024 cell surface, and the rest are degraded in the endoplasmic
HDEC 64.0 31024 88.031024
reticulum [50, 51].
Abbreviations are: ECs, endothelial cells; EPO, erythropoietin; HUVEC, Quantitative determination of mRNA expressionhuman umbilical vein endothelial cells; HPAEC, human pulmonary artery endo-
thelial cells; HCAEC, human coronary artery endothelial cells; HDEC, human failed to detect any increase in EPOR gene expression
dermis endothelial cells. The values of human EPO receptor-specific mRNA in EPO-treated HUVEC, HPAEC, and HDEC cultures.were obtained from Figure 4B. Each sample was assayed three times from two
separate experiments. In contrast, a twofold increase of EPOR mRNA was
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Fig. 5. Polymerase chain reaction (PCR) analysis of endothelin-1 (ET-1) transcripts in untreated and EPO-treated HUVEC, HPAEC, HDEC,
and HCAEC. Monolayers of HUVEC, HCAEC, HDEC, and HPAEC cells were either incubated with EPO (4 U/mL) for four hours or were
untreated, and mRNA was prepared as described in the Methods section. Reverse transcription of total RNA isolated from respective endothelial
cells with ET-1–specific primers and multiple reactions for PCR amplification of cDNA were carried out with ET-1 primers and standard DNA
as described in Figure 4. (A) The amplification products were resolved by agarose gel electrophoresis. Left panels show controls and right panels
show EPO treated (upper band 450 bp standard DNA and lower band 290 bp ET-1 cDNA; bp, size markers). (B) Quantitation was achieved as
described in Figure 4. ET-1 cDNA and the standard DNA bands were cut, the radioactivity present in each band was determined and plotted
against the amount of standard added to each reaction mixture. Symbols are: (d) standard DNA; (j) ET-1-specific PCR product to each reaction
mixture.
Table 3. Effect of EPO on ET-1 production by endothelial cells




ECs Endothelin-1 pg/2 3 10 5 cells
ECs ng cDNA/lg of mRNA
HUVEC 35 37
HUVEC 2.8 31022 6.231022 HPAEC 39 36
HPAEC 3.8 31022 4.731022 HCAEC 48 50
HCAEC 2.6 31022 2.731022 HDEC 45 47
HDEC 0.34 31022 0.4331022
HUVEC, HPAEC, HCAEC, and HDEC were incubated in serum-free endo-
thelial cell basal media (EBM) with 4 U/mL rHuEPO for 4 hours. Control cellsThe values of human ET-1-specific mRNA were derived from Figure 5B.
were exposed to rHuEPO vehicle alone. Results represent the mean of twoEach sample was assayed three times from two separate experiments. Abbrevia-
experiments performed in duplicate. Abbreviations are in Table 1.tions are in Table 1.
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Fig. 6. Polymerase chain reaction (PCR) analysis of nitric oxide synthase (NOS) transcripts in EPO-treated and nontreated HUVEC, HPAEC,
HDEC, and HCAEC. Monolayers of HUVEC, HCAEC, HDEC, and HPAEC were either incubated with EPO (4 U/mL) for four hours or were
untreated, and mRNA was prepared as described in the Methods section. Reverse transcription of total RNA isolated from respective endothelial
cells with NOS-specific primers and multiple reactions for PCR amplification of cDNA were carried out with NOS primers and standard DNA,
as described in Figure 5. (A) The amplification products were analyzed by agarose gel electrophoresis. Left panels show controls and right panels
show EPO treated (upper 500 bp band standard DNA and lower 200 bp NOS cDNA band; bp, size markers). (B) For quantitation, the NOS and
the standard bands were cut, the radioactivity present in each band was determined and plotted against the amount of standard added to each
reaction mixture. Symbols are: (d) standard DNA; (j) NOS-specific PCR product.
Table 5. Effect of EPO on NOS activity by endothelial cells from
various sources
Table 4. Quantitation of nitric oxide synthase (NOS)-specific
mRNA expression Control EPO-treated Change(-fold)
ECs Nitric oxide synthase fmol 3H-citrulline/min/mg proteinControl EPO-treated
HUVEC 30 78 2.6ECs ng cDNA/lg of mRNA
HPAEC 14 63 4.5
HUVEC 1.8 31023 1.631023 HDEC 30 110 3.6
HPAEC 1.0 31023 0.831023
HUVEC, HPAEC, and HDEC were incubated in complete media (EGM-2HCAEC 1.8 31023 1.931023
MV) with 4 U/mL rHuEPO. The medium was changed daily for up to 6 days.HDEC 1.2 31023 1.531023
Control cells were exposed to complete media alone. The cell extracts were
prepared and NOS activity was measured as described in the Methods section.The values of human NOS-specific mRNA were obtained from Figure 6B.
Each sample was assayed three times from two separate experiments. Abbrevia- Results represent the mean of two experiments performed in duplicate. Abbrevi-
ations are in Table 1.tions are in Table 1.
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